These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11264175)

  • 1. BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
    Deutsch E; Dugray A; AbdulKarim B; Marangoni E; Maggiorella L; Vaganay S; M'Kacher R; Rasy SD; Eschwege F; Vainchenker W; Turhan AG; Bourhis J
    Blood; 2001 Apr; 97(7):2084-90. PubMed ID: 11264175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
    Jonuleit T; van der Kuip H; Miething C; Michels H; Hallek M; Duyster J; Aulitzky WE
    Blood; 2000 Sep; 96(5):1933-9. PubMed ID: 10961897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
    Bartholomeusz GA; Talpaz M; Kapuria V; Kong LY; Wang S; Estrov Z; Priebe W; Wu J; Donato NJ
    Blood; 2007 Apr; 109(8):3470-8. PubMed ID: 17202319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
    Horita M; Andreu EJ; Benito A; Arbona C; Sanz C; Benet I; Prosper F; Fernandez-Luna JL
    J Exp Med; 2000 Mar; 191(6):977-84. PubMed ID: 10727459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway.
    Dai Z; Quackenbush RC; Courtney KD; Grove M; Cortez D; Reuther GW; Pendergast AM
    Genes Dev; 1998 May; 12(10):1415-24. PubMed ID: 9585502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
    Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
    Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
    Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
    Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
    Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.
    Iervolino A; Santilli G; Trotta R; Guerzoni C; Cesi V; Bergamaschi A; Gambacorti-Passerini C; Calabretta B; Perrotti D
    Mol Cell Biol; 2002 Apr; 22(7):2255-66. PubMed ID: 11884611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.
    Goetz AW; van der Kuip H; Maya R; Oren M; Aulitzky WE
    Cancer Res; 2001 Oct; 61(20):7635-41. PubMed ID: 11606405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
    Dou QP; McGuire TF; Peng Y; An B
    J Pharmacol Exp Ther; 1999 May; 289(2):781-90. PubMed ID: 10215653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
    Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
    Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
    Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
    Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
    Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
    Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
    Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.